← Back to Search

Benzodiazepine

Diazepam for Alcohol Withdrawal Syndrome

N/A
Waitlist Available
Led By Matthew Sloan, MD, MSc
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-5 day treatment period
Awards & highlights
No Placebo-Only Group

Summary

This trial uses telemedicine to help people manage alcohol withdrawal symptoms from home. It targets individuals who are actively drinking and have a history of withdrawal. Doctors monitor symptoms via video calls and provide medication based on the severity of the symptoms.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-5 day treatment period
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-5 day treatment period for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Retention in treatment
Transfer to a higher level of care
Secondary study objectives
Diazepam dose
Duration of active withdrawal treatment
Patient satisfaction with the telemedicine platform
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Symptom-triggered diazepam treatmentExperimental Treatment1 Intervention
Participants will be treated for a period of 3 days using a symptom-triggered withdrawal management protocol delivered over telemedicine. Participants who score 10 or above on the modified CIWA-Ar will be advised to take a specific dose of diazepam (either 10 or 20mg, at the clinician's discretion). Participants will be reassessed regularly over the 3-day period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Diazepam
2016
Completed Phase 4
~2800

Find a Location

Who is running the clinical trial?

Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,392 Previous Clinical Trials
26,527,436 Total Patients Enrolled
Centre for Addiction and Mental HealthLead Sponsor
375 Previous Clinical Trials
82,857 Total Patients Enrolled
Ontario Ministry of Health and Long Term CareOTHER_GOV
91 Previous Clinical Trials
107,994 Total Patients Enrolled
Matthew Sloan, MD, MScPrincipal InvestigatorCentre for Addiction and Mental Health

Media Library

Diazepam (Benzodiazepine) Clinical Trial Eligibility Overview. Trial Name: NCT04858490 — N/A
Alcohol Withdrawal Syndrome Research Study Groups: Symptom-triggered diazepam treatment
Alcohol Withdrawal Syndrome Clinical Trial 2023: Diazepam Highlights & Side Effects. Trial Name: NCT04858490 — N/A
Diazepam (Benzodiazepine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04858490 — N/A
~7 spots leftby Dec 2025